<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37526809</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-7209</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Angiogenesis</Title><ISOAbbreviation>Angiogenesis</ISOAbbreviation></Journal><ArticleTitle>VEGF-A plasma levels are associated with impaired DLCO and radiological sequelae in long COVID patients.</ArticleTitle><Pagination><StartPage>51</StartPage><EndPage>66</EndPage><MedlinePgn>51-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10456-023-09890-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Long COVID, also known as post-acute sequelae of COVID-19 (PASC), is characterized by persistent clinical symptoms following COVID-19.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To correlate biomarkers of endothelial dysfunction with persistent clinical symptoms and pulmonary function defects at distance from COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Consecutive patients with long COVID-19 suspicion were enrolled. A panel of endothelial biomarkers was measured in each patient during clinical evaluation and pulmonary function test (PFT).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study included 137 PASC patients, mostly male (68%), with a median age of 55&#xa0;years. A total of 194 PFTs were performed between months 3 and 24 after an episode of SARS-CoV-2 infection. We compared biomarkers evaluated in PASC patients with 20 healthy volunteers (HVs) and acute hospitalized COVID-19 patients (n&#x2009;=&#x2009;88). The study found that angiogenesis-related biomarkers and von Willebrand factor (VWF) levels were increased in PASC patients compared to HVs without increased inflammatory or platelet activation markers. Moreover, VEGF-A and VWF were associated with persistent lung CT scan lesions and impaired diffusing capacity of the lungs for carbon monoxide (DLCO) measurement. By employing a Cox proportional hazards model adjusted for age, sex, and body mass index, we further confirmed the accuracy of VEGF-A and VWF. Following adjustment, VEGF-A emerged as the most significant predictive factor associated with persistent lung CT scan lesions and impaired DLCO measurement.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">VEGF-A is a relevant predictive factor for DLCO impairment and radiological sequelae in PASC. Beyond being a biomarker, we hypothesize that the persistence of angiogenic disorders may contribute to long COVID symptoms.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Philippe</LastName><ForeName>Aur&#xe9;lien</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University Paris Cit&#xe9;, Innovative Therapies in Hemostasis, INSERM, 75006, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hematology Department, AP-HP.Centre, Universit&#xe9; Paris Cit&#xe9;, Georges Pompidou European Hospital, 75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>G&#xfc;nther</LastName><ForeName>Sven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University Paris Cit&#xe9;, Innovative Therapies in Hemostasis, INSERM, 75006, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit&#xe9; d'Explorations Fonctionnelles Respiratoires et du Sommeil, AP-HP, Georges Pompidou European Hospital, 75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rancic</LastName><ForeName>Jeanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University Paris Cit&#xe9;, Innovative Therapies in Hemostasis, INSERM, 75006, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavagna</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, AP-HP Sorbonne University, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe9; Paris Cit&#xe9;, INSERM, PARCC, 75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renaud</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Unit&#xe9; d'Explorations Fonctionnelles Respiratoires et du Sommeil, AP-HP, Georges Pompidou European Hospital, 75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gendron</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>University Paris Cit&#xe9;, Innovative Therapies in Hemostasis, INSERM, 75006, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hematology Department, AP-HP.Centre, Universit&#xe9; Paris Cit&#xe9;, Georges Pompidou European Hospital, 75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mousseaux</LastName><ForeName>Elie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Paris-Cardiovascular Research Center INSERM 970, Universit&#xe9; de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Georges Pompidou European Hospital, 75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hua-Huy</LastName><ForeName>Th&#xf4;ng</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Unit&#xe9; d'Explorations Fonctionnelles Respiratoires et du Sommeil, AP-HP, Georges Pompidou European Hospital, 75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reverdito</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Paris-Cardiovascular Research Center INSERM 970, Universit&#xe9; de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Georges Pompidou European Hospital, 75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Planquette</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University Paris Cit&#xe9;, Innovative Therapies in Hemostasis, INSERM, 75006, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Respiratory Diseases Department, AP-HP.Centre, Universit&#xe9; Paris Cit&#xe9;, Georges Pompidou European Hospital, 75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>University Paris Cit&#xe9;, Innovative Therapies in Hemostasis, INSERM, 75006, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Respiratory Diseases Department, AP-HP.Centre, Universit&#xe9; Paris Cit&#xe9;, Georges Pompidou European Hospital, 75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaussem</LastName><ForeName>Pascale</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University Paris Cit&#xe9;, Innovative Therapies in Hemostasis, INSERM, 75006, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hematology Department, AP-HP.Centre, Universit&#xe9; Paris Cit&#xe9;, Georges Pompidou European Hospital, 75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Immunology Department, AP-HP. Centre, Universit&#xe9; Paris Cit&#xe9;, H&#xf4;tel-Dieu Hospital, 75004, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diehl</LastName><ForeName>Jean-Luc</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>University Paris Cit&#xe9;, Innovative Therapies in Hemostasis, INSERM, 75006, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Intensive Care Unit, AP-HP. Centre Universit&#xe9; Paris Cit&#xe9;, Georges Pompidou European Hospital, 75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smadja</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>University Paris Cit&#xe9;, Innovative Therapies in Hemostasis, INSERM, 75006, Paris, France. david.smadja@aphp.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hematology Department, AP-HP.Centre, Universit&#xe9; Paris Cit&#xe9;, Georges Pompidou European Hospital, 75015, Paris, France. david.smadja@aphp.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>programme jeune talent</GrantID><Agency>M&#xe9;c&#xe9;nat Cr&#xe9;dit Agricole Ile de France</Agency><Country/></Grant><Grant><GrantID>SARCODO Flash Covid</GrantID><Agency>ANR and Fondation de France</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Angiogenesis</MedlineTA><NlmUniqueID>9814575</NlmUniqueID><ISSNLinking>0969-6970</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014841">von Willebrand Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014841" MajorTopicYN="N">von Willebrand Factor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiogenesis</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">DLCO</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae of SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">VEGF-A</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>1</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>1</Day><Hour>11</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37526809</ArticleId><ArticleId IdType="doi">10.1007/s10456-023-09890-9</ArticleId><ArticleId IdType="pii">10.1007/s10456-023-09890-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for disease control and prevention (CDC). Post-COVID Conditions: Information for Healthcare Providers. : https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html .</Citation></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV (2022) WHO clinical case definition working group on post-COVID-19 condition. a clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 22(4):e102-7</Citation><ArticleIdList><ArticleId IdType="pubmed">34951953</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Montani D, Savale L, Noel N, Meyrignac O, Colle R, Gasnier M et al (2022) Post-acute COVID-19 syndrome. Eur Respir Rev Off J Eur Respir Soc 31(163):210185</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0185-2021</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F (2020) Gemelli against COVID-19 Post-acute care study group. persistent symptoms in patients after acute COVID-19. JAMA 324(6):603&#x2013;5</Citation><ArticleIdList><ArticleId IdType="pubmed">32644129</ArticleId><ArticleId IdType="pmc">7349096</ArticleId><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y et al (2021) Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 27(1):89&#x2013;95</Citation></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM (2022) Lifelines corona research initiative persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet Lond Engl 400(10350):452&#x2013;61</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y et al (2021) 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet Lond Engl 398(10302):747&#x2013;758</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Li X, Gu X, Zhang H, Ren L, Guo L et al (2022) Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med 10(9):863&#x2013;876</Citation><ArticleIdList><ArticleId IdType="pubmed">35568052</ArticleId><ArticleId IdType="pmc">9094732</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(22)00126-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators, Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C et al (2022) Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 328(16):1604&#x2013;1615</Citation><ArticleIdList><ArticleId IdType="pmc">9552043</ArticleId><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateu L, Tebe C, Loste C, Santos JR, Llad&#xf3;s G, L&#xf3;pez C, et al. Determinants of the Onset and Prognosis of the Post-COVID-19 Condition: A 2-Year Prospective Cohort Study [Internet]. SSRN; 2023. Retrieved July 13, 2023, from https://www.ssrn.com/abstract=4505315</Citation></Reference><Reference><Citation>Yang C, Zhao H, Esp&#xed;n E, Tebbutt SJ (2023) Association of SARS-CoV-2 infection and persistence with long COVID. Lancet Respir Med. https://doi.org/10.1016/S2213-2600(23)00142-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00142-X</ArticleId><ArticleId IdType="pubmed">38101437</ArticleId><ArticleId IdType="pmc">10171832</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G et al (2023) Persistent Circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis Off Publ Infect Dis Soc Am 76(3):e487&#x2013;e490</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel MA, Knauer MJ, Nicholson M, Daley M, Van Nynatten LR, Cepinskas G et al (2023) Organ and cell-specific biomarkers of Long-COVID identified with targeted proteomics and machine learning. Mol Med 29(1):26</Citation><ArticleIdList><ArticleId IdType="pubmed">36809921</ArticleId><ArticleId IdType="pmc">9942653</ArticleId><ArticleId IdType="doi">10.1186/s10020-023-00610-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Gy&#xf6;ngy&#xf6;si M, Alcaide P, Asselbergs FW, Brundel BJJM, Camici GG, da Costa Martins P et al (2023) Long COVID and the cardiovascular system-elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: a joint Scientific Statement of the ESC Working Groups on cellular biology of the heart and myocardial and pericardial diseases. Cardiovasc Res 119(2):336&#x2013;56</Citation><ArticleIdList><ArticleId IdType="pubmed">35875883</ArticleId><ArticleId IdType="doi">10.1093/cvr/cvac115</ArticleId></ArticleIdList></Reference><Reference><Citation>Chioh FW, Fong SW, Young BE, Wu KX, Siau A, Krishnan S et al (2021) Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. eLife 10:e64909</Citation><ArticleIdList><ArticleId IdType="pubmed">33752798</ArticleId><ArticleId IdType="pmc">7987341</ArticleId><ArticleId IdType="doi">10.7554/eLife.64909</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F et al (2020) Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 383(2):120&#x2013;128</Citation><ArticleIdList><ArticleId IdType="pubmed">32437596</ArticleId><ArticleId IdType="pmc">7412750</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId></ArticleIdList></Reference><Reference><Citation>Smadja DM, Mentzer SJ, Fontenay M, Laffan MA, Ackermann M, Helms J et al (2021) COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. Angiogenesis 24(4):755&#x2013;788</Citation><ArticleIdList><ArticleId IdType="pubmed">34184164</ArticleId><ArticleId IdType="pmc">8238037</ArticleId><ArticleId IdType="doi">10.1007/s10456-021-09805-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Philippe A, Chocron R, Gendron N, Bory O, Beauvais A, Peron N et al (2021) Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis 24(3):505&#x2013;517</Citation><ArticleIdList><ArticleId IdType="pubmed">33449299</ArticleId><ArticleId IdType="pmc">7809553</ArticleId><ArticleId IdType="doi">10.1007/s10456-020-09762-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Werlein C, Ackermann M, Stark H, Shah HR, Tzankov A, Haslbauer JD et al (2022) Inflammation and vascular remodeling in COVID-19 hearts. Angiogenesis 12:1&#x2013;16</Citation></Reference><Reference><Citation>Smadja DM, Philippe A, Bory O, Gendron N, Beauvais A, Gruest M et al (2021) Placental growth factor level in plasma predicts COVID-19 severity and in-hospital mortality. J Thromb Haemost JTH 19(7):1823&#x2013;1830</Citation><ArticleIdList><ArticleId IdType="pubmed">33830623</ArticleId><ArticleId IdType="doi">10.1111/jth.15339</ArticleId></ArticleIdList></Reference><Reference><Citation>Faconti L, Farukh B, McNally RJ, Brett S, Chowienczyk PJ (2023) Impaired &#x3b2;2-adrenergic endothelium-dependent vasodilation in patients previously hospitalized with coronavirus disease 2019. J Hypertens. https://doi.org/10.1097/HJH.0000000000003420</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000003420</ArticleId><ArticleId IdType="pubmed">37016904</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H, Townsend L, Morrin H, Ahmad A, Comerford C, Karampini E et al (2021) Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost JTH 19(10):2546&#x2013;2553</Citation><ArticleIdList><ArticleId IdType="pubmed">34375505</ArticleId><ArticleId IdType="doi">10.1111/jth.15490</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H, Ward SE, Townsend L, Karampini E, Elliott S, Conlon N et al (2022) Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction. J Thromb Haemost 20(10):2429&#x2013;2438</Citation><ArticleIdList><ArticleId IdType="pubmed">35875995</ArticleId><ArticleId IdType="pmc">9349977</ArticleId><ArticleId IdType="doi">10.1111/jth.15830</ArticleId></ArticleIdList></Reference><Reference><Citation>Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH et al (2012) Multi-ethnic reference values for spirometry for the 3&#x2013;95-yr age range: the global lung function 2012 equations. Eur Respir J 40(6):1324&#x2013;1343</Citation><ArticleIdList><ArticleId IdType="pubmed">22743675</ArticleId><ArticleId IdType="pmc">3786581</ArticleId><ArticleId IdType="doi">10.1183/09031936.00080312</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanojevic S, Graham BL, Cooper BG, Thompson BR, Carter KW, Francis RW et al (2017) Official ERS technical standards: global lung function initiative reference values for the carbon monoxide transfer factor for Caucasians. Eur Respir J 50(3):1700010</Citation><ArticleIdList><ArticleId IdType="pubmed">28893868</ArticleId><ArticleId IdType="doi">10.1183/13993003.00010-2017</ArticleId></ArticleIdList></Reference><Reference><Citation>ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1; 166(1):111&#x2013;7</Citation></Reference><Reference><Citation>Enright PL, Sherrill DL (1998) Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 158(5 Pt 1):1384&#x2013;1387</Citation><ArticleIdList><ArticleId IdType="pubmed">9817683</ArticleId><ArticleId IdType="doi">10.1164/ajrccm.158.5.9710086</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N et al (2020) Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology 295(3):200463</Citation><ArticleIdList><ArticleId IdType="pubmed">32077789</ArticleId><ArticleId IdType="doi">10.1148/radiol.2020200463</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X et al (2020) Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study. Radiology 296(2):E55-64</Citation><ArticleIdList><ArticleId IdType="pubmed">32191587</ArticleId><ArticleId IdType="doi">10.1148/radiol.2020200843</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerin CL, Guyonnet L, Goudot G, Revets D, Konstantinou M, Chipont A et al (2021) Multidimensional proteomic approach of endothelial progenitors demonstrate expression of KDR restricted to CD19 Cells. Stem Cell Rev Rep 17(2):639&#x2013;651</Citation><ArticleIdList><ArticleId IdType="pubmed">33205351</ArticleId><ArticleId IdType="doi">10.1007/s12015-020-10062-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudley AC, Griffioen AW (2023) Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis 15:1&#x2013;35</Citation></Reference><Reference><Citation>Ackermann M, Kamp JC, Werlein C, Walsh CL, Stark H, Prade V et al (2022) The fatal trajectory of pulmonary COVID-19 is driven by lobular ischemia and fibrotic remodelling. EBioMedicine 4(85):104296</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104296</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamp JC, Werlein C, Plucinski EKJ, Neubert L, Welte T, Lee PD et al (2023) Novel insight into pulmonary fibrosis and long COVID. Am J Respir Crit Care Med 207(8):1105&#x2013;1107</Citation><ArticleIdList><ArticleId IdType="pubmed">36731065</ArticleId><ArticleId IdType="pmc">10112435</ArticleId><ArticleId IdType="doi">10.1164/rccm.202212-2314LE</ArticleId></ArticleIdList></Reference><Reference><Citation>Barratt S, Medford AR, Millar AB (2014) Vascular endothelial growth factor in acute lung injury and acute respiratory distress syndrome. Respir Int Rev Thorac Dis 87(4):329&#x2013;342</Citation></Reference><Reference><Citation>Miao H, Qiu F, Zhu L, Jiang B, Yuan Y, Huang B et al (2021) Novel angiogenesis strategy to ameliorate pulmonary hypertension. J Thorac Cardiovasc Surg 161(6):e417&#x2013;e434</Citation><ArticleIdList><ArticleId IdType="pubmed">32359908</ArticleId><ArticleId IdType="doi">10.1016/j.jtcvs.2020.03.044</ArticleId></ArticleIdList></Reference><Reference><Citation>Eddahibi S, Humbert M, Sediame S, Chouaid C, Partovian C, Ma&#xee;tre B et al (2000) Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. effect of prostacyclin therapy. Am J Respir Crit Care Med 162:1493&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">11029367</ArticleId><ArticleId IdType="doi">10.1164/ajrccm.162.4.2003124</ArticleId></ArticleIdList></Reference><Reference><Citation>Christou H, Yoshida A, Arthur V, Morita T, Kourembanas S (1998) Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol 18(6):768&#x2013;776</Citation><ArticleIdList><ArticleId IdType="pubmed">9618381</ArticleId><ArticleId IdType="doi">10.1165/ajrcmb.18.6.2980</ArticleId></ArticleIdList></Reference><Reference><Citation>Smadja DM, Gaussem P, Mauge L, Isra&#xeb;l-Biet D, Dignat-George F, Peyrard S et al (2009) Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 119(3):374&#x2013;381</Citation><ArticleIdList><ArticleId IdType="pubmed">19139384</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.808246</ArticleId></ArticleIdList></Reference><Reference><Citation>Godinas L, Guignabert C, Seferian A, Perros F, Bergot E, Sibille Y et al (2013) Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword? Semin Respir Crit Care Med 34(5):714&#x2013;724</Citation><ArticleIdList><ArticleId IdType="pubmed">24037637</ArticleId><ArticleId IdType="doi">10.1055/s-0033-1356494</ArticleId></ArticleIdList></Reference><Reference><Citation>Papaioannou AI, Kostikas K, Kollia P, Gourgoulianis KI (2006) Clinical implications for vascular endothelial growth factor in the lung: friend or foe? Respir Res 7(1):128</Citation><ArticleIdList><ArticleId IdType="pubmed">17044926</ArticleId><ArticleId IdType="pmc">1629021</ArticleId><ArticleId IdType="doi">10.1186/1465-9921-7-128</ArticleId></ArticleIdList></Reference><Reference><Citation>Smadja DM, Nunes H, Juvin K, Bertil S, Valeyre D, Gaussem P et al (2014) Increase in both angiogenic and angiostatic mediators in patients with idiopathic pulmonary fibrosis. Pathol Biol (Paris) 62(6):391&#x2013;394</Citation><ArticleIdList><ArticleId IdType="pubmed">25239280</ArticleId><ArticleId IdType="doi">10.1016/j.patbio.2014.07.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukihara J, Kondoh Y (2016) Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis. Expert Rev Respir Med 10(12):1247&#x2013;1254</Citation><ArticleIdList><ArticleId IdType="pubmed">27744713</ArticleId><ArticleId IdType="doi">10.1080/17476348.2016.1249854</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfadda AA, Rafiullah M, Alkhowaiter M, Alotaibi N, Alzahrani M, Binkhamis K et al (2022) Clinical and biochemical characteristics of people experiencing post-coronavirus disease 2019-related symptoms: a prospective follow-up investigation. Front Med 9:1067082</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1067082</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel MA, Knauer MJ, Nicholson M, Daley M, Van Nynatten LR, Martin C et al (2022) Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism. Mol Med 28(1):122</Citation><ArticleIdList><ArticleId IdType="pubmed">36217108</ArticleId><ArticleId IdType="pmc">9549814</ArticleId><ArticleId IdType="doi">10.1186/s10020-022-00548-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Guevara-Coto J, Yogendra R, Francisco EB, Long E, Pise A et al (2021) Immune-based prediction of COVID-19 severity and Chronicity decoded using machine learning. Front Immunol 28(12):700782</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.700782</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Yogendra R, Guevara-Coto J, Mora-Rodriguez RA, Osgood E, Bream J et al (2023) Case series: maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC). Front Med 10:1122529</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1122529</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Konnova A, Smet M, Berkell M, Savoldi A, Morra M et al (2023) Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments. J Clin Invest 133(6):e166032</Citation><ArticleIdList><ArticleId IdType="pubmed">36727404</ArticleId><ArticleId IdType="pmc">10014108</ArticleId><ArticleId IdType="doi">10.1172/JCI166032</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A, Vojdani E, Saidara E, Maes M (2023) Persistent SARS-CoV-2 infection, EBV, HHV-6 and other factors may contribute to inflammation and autoimmunity in long COVID. Viruses 15(2):400</Citation><ArticleIdList><ArticleId IdType="pubmed">36851614</ArticleId><ArticleId IdType="pmc">9967513</ArticleId><ArticleId IdType="doi">10.3390/v15020400</ArticleId></ArticleIdList></Reference><Reference><Citation>Osiaevi I, Schulze A, Evers G, Harmening K, Vink H, K&#xfc;mpers P et al (2023) Persistent capillary rarefication in long COVID syndrome. Angiogenesis 26(1):53&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pubmed">35951203</ArticleId><ArticleId IdType="doi">10.1007/s10456-022-09850-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M et al (2004) Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 169(11):1203&#x2013;1208</Citation><ArticleIdList><ArticleId IdType="pubmed">14754760</ArticleId><ArticleId IdType="doi">10.1164/rccm.200308-1111OC</ArticleId></ArticleIdList></Reference><Reference><Citation>Charfeddine S, Ibn Hadj Amor H, Jdidi J, Torjmen S, Kraiem S, Hammami R et al (2021) Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? insights from TUN-EndCOV study. Front Cardiovasc Med 8:745758</Citation><ArticleIdList><ArticleId IdType="pubmed">34917659</ArticleId><ArticleId IdType="pmc">8670225</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2021.745758</ArticleId></ArticleIdList></Reference><Reference><Citation>Charfeddine S, Ibnhadjamor H, Jdidi J, Torjmen S, Kraiem S, Bahloul A et al (2022) Sulodexide significantly improves endothelial dysfunction and alleviates chest pain and palpitations in patients with long-COVID-19: insights from TUN-EndCOV study. Front Cardiovasc Med 9:866113</Citation><ArticleIdList><ArticleId IdType="pubmed">35647070</ArticleId><ArticleId IdType="pmc">9133483</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2022.866113</ArticleId></ArticleIdList></Reference><Reference><Citation>Willems LH, Nagy M, Ten Cate H, Spronk HMH, Groh LA, Leentjens J et al (2022) Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3&#xa0;months after COVID-19. Thromb Res 209:106&#x2013;114</Citation><ArticleIdList><ArticleId IdType="pubmed">34922160</ArticleId><ArticleId IdType="doi">10.1016/j.thromres.2021.11.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Willems LH, Jacobs LMC, Groh LA, Ten Cate H, Spronk HMH, Wilson-Storey B et al (2023) Vascular function, systemic inflammation, and coagulation activation 18&#xa0;months after COVID-19 infection: an observational cohort study. J Clin Med 12(4):1413</Citation><ArticleIdList><ArticleId IdType="pubmed">36835948</ArticleId><ArticleId IdType="pmc">9965558</ArticleId><ArticleId IdType="doi">10.3390/jcm12041413</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan BE, Wong SW, Sum CLL, Lim GH, Leung BP, Tan CW et al (2022) Hypercoagulability, endotheliopathy, and inflammation approximating 1&#xa0;year after recovery: assessing the long-term outcomes in COVID-19 patients. Am J Hematol 97(7):915&#x2013;923</Citation><ArticleIdList><ArticleId IdType="pubmed">35477923</ArticleId><ArticleId IdType="pmc">9073976</ArticleId><ArticleId IdType="doi">10.1002/ajh.26575</ArticleId></ArticleIdList></Reference><Reference><Citation>Philippe A, Gendron N, Bory O, Beauvais A, Mirault T, Planquette B et al (2021) Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance. Angiogenesis 24(3):407&#x2013;411</Citation><ArticleIdList><ArticleId IdType="pubmed">33974165</ArticleId><ArticleId IdType="pmc">8111656</ArticleId><ArticleId IdType="doi">10.1007/s10456-021-09789-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Constantinescu-Bercu A, Kessler A, de Groot R, Dragunaite B, Heightman M, Hillman T et al (2023) Analysis of thrombogenicity under flow reveals new insights into the prothrombotic state of patients with post-COVID syndrome. J Thromb Haemost 21(1):94&#x2013;100</Citation><ArticleIdList><ArticleId IdType="pubmed">36695401</ArticleId><ArticleId IdType="doi">10.1016/j.jtha.2022.10.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasannan N, Heightman M, Hillman T, Wall E, Bell R, Kessler A et al (2022) Impaired exercise capacity in post-COVID-19 syndrome: the role of VWF-ADAMTS13 axis. Blood Adv 6(13):4041&#x2013;4048</Citation><ArticleIdList><ArticleId IdType="pubmed">35543533</ArticleId><ArticleId IdType="pmc">9098525</ArticleId><ArticleId IdType="doi">10.1182/bloodadvances.2021006944</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzi O, Frieden M, Villemin P, Fournier M, Foti M, Vischer UM (2008) Protein kinase C-delta mediates von Willebrand factor secretion from endothelial cells in response to vascular endothelial growth factor (VEGF) but not histamine. J Thromb Haemost 6(11):1962&#x2013;1969</Citation><ArticleIdList><ArticleId IdType="pubmed">18752579</ArticleId><ArticleId IdType="doi">10.1111/j.1538-7836.2008.03138.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Jian Sun H, Rong Li Z, Zhang H, Jun Yang W, Ni B et al (2015) Gastric cancer-associated enhancement of von Willebrand factor is regulated by vascular endothelial growth factor and related to disease severity. BMC Cancer 15:80</Citation><ArticleIdList><ArticleId IdType="pubmed">25886574</ArticleId><ArticleId IdType="pmc">4340498</ArticleId><ArticleId IdType="doi">10.1186/s12885-015-1083-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushita K, Yamakuchi M, Morrell CN, Ozaki M, O&#x2019;Rourke B, Irani K et al (2005) Vascular endothelial growth factor regulation of Weibel-Palade-body exocytosis. Blood 105(1):207&#x2013;214</Citation><ArticleIdList><ArticleId IdType="pubmed">15345585</ArticleId><ArticleId IdType="doi">10.1182/blood-2004-04-1519</ArticleId></ArticleIdList></Reference><Reference><Citation>Geindreau M, Ghiringhelli F, Bruchard M (2021) Vascular endothelial growth factor, a key modulator of the anti-tumor immune response. Int J Mol Sci 22(9):4871</Citation><ArticleIdList><ArticleId IdType="pubmed">34064508</ArticleId><ArticleId IdType="pmc">8124522</ArticleId><ArticleId IdType="doi">10.3390/ijms22094871</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang J, Xu F, Aondio G, Li Y, Fumagalli A, Lu M et al (2021) Efficacy and tolerability of bevacizumab in patients with severe Covid-19. Nat Commun 12(1):814</Citation><ArticleIdList><ArticleId IdType="pubmed">33547300</ArticleId><ArticleId IdType="pmc">7864918</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-21085-8</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>